國家衛生研究院 NHRI:
English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 12189/12972 (94%)
造訪人次 : 968036      線上人數 : 847
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧：
  • 您可在西文檢索詞彙前後加上"雙引號"，以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋，建議至進階搜尋限定作者欄位，可獲得較完整資料
    •  進階搜尋
    主頁 ‧ 登入 ‧ 上傳 ‧ 說明 ‧ 關於NHRI ‧ 管理 到手機版
    鄰近類別
    圖書 [1/1]
    期刊論文 [328/331]

    類別統計

    近3年內發表的文件:16(8.94%)
    含全文筆數:115(64.25%)

    文件下載次數統計
    下載大於0次:115(100.00%)
    下載大於100次:112(97.39%)
    檔案下載總次數:39419(22.08%)

    最後更新時間: 2024-12-03 22:16


    上傳排行

    資料載入中.....

    下載排行

    資料載入中.....

    RSS Feed RSS Feed
    跳至:
    或輸入年份:
    由新到舊排序 由最舊的開始

    顯示項目51-75 / 179. (共8頁)
    << < 1 2 3 4 5 6 7 8 > >>
    每頁顯示[10|25|50]項目

    日期題名關聯
    2018-06 The effect of best response to prior anticancer therapy on efficacy outcomes in the napoli-1 trial of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy Annals of Oncology. 2018 Jun;29(Suppl. 5):Meeting Abstract P-152.
    2018-06 Decreased appetite (DA) at baseline impacts prognosis in the NAPOLI-1 phase 3 study in metastatic pancreatic ductal adenocarcinoma (mPDAC) Annals of Oncology. 2018 Jun;29(Suppl. 5):Meeting Abstract P-153.
    2018-06 Prognostic effect of primary tumor location in the NAPOLI-1 phase 3 study in metastatic pancreatic ductal adenocarcinoma (mPDAC) Annals of Oncology. 2018 Jun;29(Suppl. 5):Meeting Abstract P-150.
    2018-06 Selected subgroup analyses of liposomal irinotecan (nal-IRI) in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) in the global NAPOLI-1 phase III trial Annals of Oncology. 2018 Jun;29(Suppl. 5):Meeting Abstract O-004.
    2018-06 Prognostic value of baseline biliary stents on outcomes in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) in the NAPOLI-1 trial Annals of Oncology. 2018 Jun;29(Suppl. 5):Meeting Abstract P-151.
    2018-05 Nivolumab safety profile in Asian and Western patients with chemotherapy-refractory (CTx-R) advanced gastric/gastroesophageal junction (adv G/GEJ) cancer from the ATTRACTION-2 and CheckMate-032 trials Journal of Clinical Oncology. 2018 May;36(15, Suppl.):Abstract number e15127.
    2018-05 A phase Ib study of ADI-PEG 20 plus pembrolizumab in advanced solid cancers Journal of Clinical Oncology. 2018 May;36(15, Suppl. S):Meeting Abstract 2556.
    2018-05 A survival prediction nomogram for liposomal irinotecan (nal-IRI)+5-fluorouracil/leucovorin (5-FU/LV) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy Journal of Clinical Oncology. 2018 May;36(15, Suppl.):Meeting Abstract e16204.
    2018-02 Subgroup analysis by measurable metastatic lesion (ML) number and selected lesion locations (LL) at baseline (BL) in NAPOLI-1: A phase III study of liposomal irinotecan (nal-IRI)+/- 5-fluorouracil/leucovorin (5-FU/LV) in patients (pts) with metastatic pan Journal of Clinical Oncology. 2018 Feb;36(4, Suppl.):Abstract number 460.
    2018-02 Nomogram for predicting overall survival (OS) in patients (pts) treated with liposomal irinotecan (nal-IRI) +/- 5-fluorouracil/leucovorin (5-FU/LV) in metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy in NAPOLI-1. Journal of Clinical Oncology. 2018 Feb;36(4, Suppl.):Abstract number 459.
    2018-02 Nivolumab safety profile in Asian and Western patients with chemotherapy-refractory (CTx-R) advanced gastric/gastroesophageal junction (adv G/GEJ) cancer from the ATTRACTION-2 and CheckMate-032 trials Journal of Clinical Oncology. 2018 Feb;36(4, Suppl.):Abstract number 90.
    2018-02 Dose modifications of liposomal irinotecan (nal-IRI)+5-fluorouracil/leucovorin (5-FU/LV) in NAPOLI-1: Impact on efficacy Journal of Clinical Oncology. 2018 Feb;36(4, Suppl.):388.
    2018-02 Subgroup analysis by baseline pain intensity (BPI) and analgesic use (BAU) in NAPOLI-1: A phase III study of liposomal irinotecan (nal IRI)+/- 5-fluorouracil/leucovorin (5-FU/LV) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) p Journal of Clinical Oncology. 2018 Feb;36(4, Suppl.):379.
    2018-02 Subgroup analysis by baseline (BL) weight-associated parameters: A phase III study of liposomal irinotecan (nal-IRI)+/--5fluorouracil/leucovorin (5-FU/LV) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with g Journal of Clinical Oncology. 2018 Feb;36(4, Suppl.):410.
    2018-01 Role of academic institute in cancer therapy development in National Institute of Cancer Research, NHRI in Taiwan Cancer Science. 2018 Jan;109(Suppl. 1):43.
    2018-01 Environmental tobacco smoke and risk of pancreatic cancer among never smokers Cancer Science. 2018 Jan;109(Suppl. 1):769.
    2018-01 The role of aberrant mitochondrial phosphoenolpyruvate carboxykinase expression in pancreatic neuroendocrine tumors Cancer Science. 2018 Jan;109(Suppl. 1):466.
    2017-11 Subgroup analysis by prior non-liposomal irinotecan therapy in NAPOLI-1: A phase 3 study of nal-IRI65-fluorouracil/leucovorin in patients with metastatic pancreatic ductal adenocarcinoma previously treated with gemcitabine-based therapy Annals of Oncology. 2017 Nov;28(Suppl. 10):67-U261.
    2017-11 CA19-9 decrease and overall survival (OS) in the NAPOLI-1 trial of liposomal irinotecan (nal-IRI) � 5-fluorouracil and leucovorin (5-FU/LV) in metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy Annals of Oncology. 2017 Nov;28(Suppl. 10):Meeting Abstract 227P.
    2017-09 ATTRACTION-04 (ONO-4538-37): A randomized, multicenter, phase 2/3 study of nivolumab (Nivo) plus chemotherapy in patients (Pts) with previously untreated advanced or recurrent gastric (G) or gastroesophageal junction (GEJ) cancer Annals of Oncology. 2017 Sep;28(Suppl. 5):Meeting Abstract 777TiP.
    2017-09 ATTRACTION-05 (ONO-4538-38/BMS CA209844): A randomized, multicenter, double-blind, placebo-controlled Phase 3 study of Nivolumab (Nivo) in combination with adjuvant chemotherapy in pStage III gastric and esophagogastric junction (G/EGJ) cancer Annals of Oncology. 2017 Sep;28(Suppl. 5):Meeting Abstract 778TiP.
    2017-09 Inhibition of the ubiquitin-conjugating enzyme E2B restores the BCNU sensitivity of cancer cells by regulating MGMT ubiquitination Annals of Oncology. 2017 Sep;28(Suppl. 5):Meeting Abstract 55P.
    2017-09 Prognostic value of baseline neutrophil-to-lymphocyte ratio for predicting clinical outcome in metastatic pancreatic ductal adenocarcinoma (mPDAC) patients treated with liposomal irinotecan (nal-IRI)+5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV alon Annals of Oncology. 2017 Sep;28(Suppl. 5):Meeting Abstract 741P.
    2017-09 Mutant KIT translocates into the nucleus and induces NFKBIB expression that leads to KIT expression in imatinib-resistant gastrointestinal stromal tumors Annals of Oncology. 2017 Sep;28(Suppl. 5):Meeting Abstract 1679P.
    2017-09 Interim safety and clinical activity of nivolumab (Nivo) in combination with S-1/capecitabine plus oxaliplatin in patients (pts) with previously untreated unresectable advanced or recurrent gastric/gastroesophageal junction (G/GEJ) cancer: part 1 study of ATTRACTION-04 (ONO-4538-37) Annals of Oncology. 2017 Sep;28(Suppl. 5):Meeting Abstract 671P.

    顯示項目51-75 / 179. (共8頁)
    << < 1 2 3 4 5 6 7 8 > >>
    每頁顯示[10|25|50]項目

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋